A pharmacoeconomic study of olopatadine hydrochloride 0.1% eye drops and bepotastine besilate 1.5% eye drops in the management of allergic conjunctivitis: A cost-effectiveness analysis
Asian Journal of Medical Sciences · 01.03.2026 · 17 (3) · 171-176
DOI: 10.71152/ajms.v17i3.5083 ↗Kurz gefasst
Fachartikel in der Zeitschrift Asian Journal of Medical Sciences, online erschienen am 01.03.2026. Verfasst von Sudipto Chatterjee und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Allergic conjunctivitis (AC) affects 10–20% of the Indian population, necessitating cost-effective treatment strategies. Aims and Objectives: We aimed to evaluate the comparison between the pharmacoeconomic profiles of olopatadine hydrochloride 0.1% and bepotastine besilate 1.5% eye drops in the management of AC. Materials and Methods: This prospective and comparative study was conducted involving patients aged 18–60 years, who were randomly assigned to receive olopatadine (Group A) or bepotastine (Group B) over a 2-week treatment period. Symptom severity scores were recorded at baseline and on day 14. The average cost-effectiveness ratio (ACER) was calculated from the perspective of healthcare payers, incorporating direct drug costs and clinical outcomes.
Results
Two treatment arms demonstrated comparable clinical efficacy, with no statistically significant differences in symptom resolution (P>0.05). Complete alleviation of symptoms was observed in both cohorts. However, olopatadine exhibited superior cost-effectiveness, reflected in lower ACER values (median 0.12; range 0.09–0.16) compared to bepotastine (median 0.19; range 0.14–0.24). Analysis of brand-level pricing revealed substantial variability, with daily costs for olopatadine ranging from INR 9 to INR 16 and for bepotastine from INR 13 to INR ₹22. The most cost-efficient brands were olopatadine Brand 5 (ACER 0.09023) and bepotastine Brand 4 (ACER 0.13207).
Conclusion
While both olopatadine 0.1% and bepotastine 1.5% were equally effective in treating AC, olopatadine demonstrated greater cost-efficiency and more consistent pricing across brands. These findings support the preferential use of olopatadine as a first-line therapeutic agent in resource-constrained settings, highlighting the importance of generic formulations and competitive pricing in optimizing healthcare resource allocation.
Zitieren
APA
Chatterjee, S., Paul, P., Bhattacharjee, A., & Mahapatra, S. (2026). A pharmacoeconomic study of olopatadine hydrochloride 0.1% eye drops and bepotastine besilate 1.5% eye drops in the management of allergic conjunctivitis: A cost-effectiveness analysis. Asian Journal of Medical Sciences, 17(3), 171-176. https://doi.org/10.71152/ajms.v17i3.5083
Vancouver
Chatterjee S, Paul P, Bhattacharjee A, Mahapatra S. A pharmacoeconomic study of olopatadine hydrochloride 0.1% eye drops and bepotastine besilate 1.5% eye drops in the management of allergic conjunctivitis: A cost-effectiveness analysis. Asian Journal of Medical Sciences. 2026;17(3):171-176. doi:10.71152/ajms.v17i3.5083
BibTeX
@article{Chatterjee2026,
author = {Chatterjee, Sudipto and Paul, Pritama and Bhattacharjee, Abhishek and Mahapatra, Soumyadeep},
title = {A pharmacoeconomic study of olopatadine hydrochloride 0.1% eye drops and bepotastine besilate 1.5% eye drops in the management of allergic conjunctivitis: A cost-effectiveness analysis},
journal = {Asian Journal of Medical Sciences},
year = {2026},
volume = {17},
number = {3},
pages = {171--176},
doi = {10.71152/ajms.v17i3.5083}
}
EUVIMED